Education Blog for Healthcare Professionals

Skyla – A New IUD, Suitable for Women at Risk for DVT and PE

Dr. Stephan Moll writes… Skyla® is a new IUD (intrauterine device) contraceptive, approved in February 2013 by the FDA.  Skyla® is like a small version of the Mirena® IUD.  It has the following features:

  • It is a small, flexible plastic T-shaped device, measuring 28 x 30 mm (Mirena®: 32 x 32 mm);
  • It contains 13.5 mg of the progestin levonorgestrel (Mirena®: 52 mg); it releases the progestin at an average rate of ca. 6 mcg/ day over three years (Mirena®: ca. 20 mcg per day, progressively decreasing to half that value after five years).
  • It is good for 3 years (Mirena®: 5 years).
  • Given its small size, it is particularly suitable for nulliparous women.

Given that that progestin-releasing IUDs do not increase the risk for venous thromboembolism [ref 1], they are a particularly attractive option in women with a history of thrombosis (DVT, PE, etc) or thombophilia (hypercoagulable states).  Thus, the Skyla® IUD seems like a very good choice as well.  Thrombosis is not listed as a possible adverse outcome associated with Skyla® use.

Further resources

  • Commercial Skyla® website: here
  • Full Skyla® prescribing information: here
  • Clot Connect discussion of progestin-contraceptives: here

Reference

  1. van Hylckama-Vlieg A et al. The risk of deep vein thrombosis associated with injectable depot-medtoxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010(Nov);30:2297-2230.

 

Disclosure:  I have no conflict of interest.

Last updated:  June 3rd, 2013

 

Tags: , ,

This entry was posted by Clot Connect on at and is filed under Uncategorized, Women and blood clots. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.